Chads Vasc Calculator
Atrial fibrillation makes blood pool and clot in the heart, and those clots cause strokes. The CHA2DS2-VASc score is the validated clinical tool cardiologists use to estimate a patient’s annual stroke risk from eight risk factors, and it is the score the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline endorses for stroke-risk prediction. Answer the questions below and the calculator adds up the points, looks up the annual stroke rate, and shows what the guidelines say about blood-thinner therapy for that score.
Quick Answer
- Quick Answer
- What each letter of CHA2DS2-VASc counts
- Score to annual stroke rate: the full table
- Worked example: 70-year-old woman with hypertension and diabetes
- What competing calculators get wrong
- Why bleeding risk is half the decision
- Frequently Asked Questions
- Add This Calculator to Your Website
- References
What each letter of CHA2DS2-VASc counts
The score tallies eight risk factors. C is congestive heart failure (1), H is hypertension (1), A2 is age 75 or older (2), D is diabetes (1), S2 is prior stroke, TIA, or thromboembolism (2), V is vascular disease such as prior heart attack, peripheral artery disease, or aortic plaque (1), A is age 65 to 74 (1), and Sc is sex category, female (1). The maximum is 9. Age and prior stroke carry double weight because they are the two strongest predictors: risk from age itself keeps climbing, and a previous clot is the clearest signal another is likely.
The mnemonic matters because a common mistake on free calculators is treating every factor as 1 point. A 76-year-old man with a prior stroke scores 4, not 2, and that is the difference between “consider anticoagulation” and “anticoagulation recommended.” Our calculator applies the double points automatically, and the breakdown under the result shows exactly which factors counted.
Score to annual stroke rate: the full table
These rates come from the Lip et al. 2010 validation cohort of non-anticoagulated patients with atrial fibrillation, and they remain the most cited reference values. Rates are strokes per 100 patient-years without treatment.
| Score | Annual stroke rate | What guidelines say |
|---|---|---|
| 0 | 0% | No anticoagulation |
| 1 (men) / 1 (women, sex only) | 1.3% | Consider; sex-only point does not count |
| 2 (men) / 2 (women) | 2.2% | Consider in women; recommended in men |
| 3 | 3.2% | Anticoagulation recommended |
| 4 | 4.0% | Anticoagulation recommended |
| 5 | 6.7% | Anticoagulation recommended |
| 6 | 9.8% | Anticoagulation recommended |
| 7 | 9.6% | Anticoagulation recommended |
| 8 | 6.7% | Anticoagulation recommended |
| 9 | 15.2% | Anticoagulation recommended |
Two things to notice. First, the rates for scores 7 and 8 are slightly lower than for 6, which is a quirk of small sample sizes at the extremes, not a real protective effect. Second, several competitor calculators round this table into three coarse buckets (“low / intermediate / high”) or omit scores 7 through 9 entirely. That loses information: the jump from 4.0% at score 4 to 9.8% at score 6 is clinically meaningful, and a tool that cannot show it is a blunt instrument.
Worked example: 70-year-old woman with hypertension and diabetes
No heart failure, no prior stroke, no vascular disease, so those contribute nothing. The total of 4 puts her firmly in the “anticoagulation recommended” range for women (threshold: 3 or higher). In practice her clinician would then weigh bleeding risk, kidney function, and any drug interactions before choosing between a DOAC and warfarin, since a DOAC is preferred for most patients without mechanical valves or mitral stenosis. Weight management and blood pressure control also matter here: excess weight raises AFib risk, which you can track with our BMI and waist circumference calculator.
What competing calculators get wrong
We tested the top-ranking CHA2DS2-VASc tools against the published criteria and found four recurring problems. First, coarse risk tables: one popular tool collapses everything into “0 = 0%, 1 = 1.3%, 2+ = 2.2% or more,” which hides the steep climb to 9.8% at score 6. Second, the sex-point trap: several tools tell a woman with a score of 1 to “consider anticoagulation” without explaining that a score made up solely of the female-sex point is treated as low risk. Third, missing applicability warnings: almost none state that the score is validated for non-valvular AF only, so people with mechanical valves get a reassuring number that does not apply to them. Fourth, stale guideline framing: the 2023 ACC/AHA guideline deliberately moved away from rigid score cutoffs toward magnitude-of-risk shared decision-making, and added flexibility to use other scores such as ATRIA or GARFIELD-AF when uncertainty exists. Tools quoting only the 2014 thresholds miss that shift.
Our calculator’s winning moves: the exact per-score annual rates from Lip 2010, automatic double-pointing for age 75+ and prior stroke, the sex-only nuance built into the guidance text, a visible factor breakdown so the score is auditable, and an explicit non-valvular-AF applicability warning. We also flag the 2024 European guideline development: ESC now endorses CHA2DS2-VA, the same score minus the sex criterion, since female sex alone never drove treatment. That change has not reached US guidelines, but it is worth knowing if your clinician mentions it.
Why bleeding risk is half the decision
A stroke-risk score is only useful paired with a bleeding-risk assessment. Guidelines recommend scores like HAS-BLED not to deny anticoagulation, but to find and fix modifiable bleeding risks: uncontrolled hypertension, alcohol use, interacting drugs such as NSAIDs, and labile INRs on warfarin. The 2023 guideline is explicit that bleeding scores should not be used in isolation to rule out anticoagulation. If you are weighing long-term medication, prescription costs vary widely between DOACs and warfarin, which our Medicare Part D cost calculator can help you estimate, and broader coverage questions are covered by our health insurance cost calculator.
- CHA2DS2-VASc runs 0 to 9; age 75+ and prior stroke/TIA count double.
- Annual stroke risk climbs from 0% at score 0 to about 9.8% at score 6; the full per-score table beats coarse low/medium/high buckets.
- A score of 1 that comes only from female sex is treated as low risk, not as a reason to start a blood thinner.
- Score 2+ in men or 3+ in women: guidelines recommend oral anticoagulation, with DOACs preferred over warfarin for most patients.
- The score applies to non-valvular AF only and never replaces a clinician’s judgment about bleeding risk.
Frequently Asked Questions
It depends on sex. In a man, a score of 2 means roughly 2.2% annual stroke risk and guidelines recommend oral anticoagulation. In a woman, a score of 2 is intermediate: if one point is female sex and only one other factor is present, anticoagulation is reasonable to consider rather than automatically recommended. Your clinician makes the final call.
A score of 0 corresponds to about 0% annual stroke rate in the validation cohort, which is why anticoagulation is generally not recommended. It does not mean risk is literally zero forever; risk factors accumulate with age, so clinicians recheck the score periodically.
Population data showed women with AFib had moderately higher stroke risk than men with the same other factors. But the point is a risk modifier, not a treatment trigger: a woman whose only point is female sex is treated as low risk. The 2024 European guidelines went further and dropped the sex criterion entirely (CHA2DS2-VA).
No. The score was developed and validated only in people with atrial fibrillation, and specifically non-valvular AFib. The annual rates do not apply to the general population, to other heart rhythms, or to people with mechanical heart valves or moderate-to-severe mitral stenosis.
CHADS2 is the older, simpler score (heart failure, hypertension, age 75+, diabetes, prior stroke doubled). CHA2DS2-VASc adds vascular disease, the 65-74 age band, and female sex, and it identifies truly low-risk patients better: in validation, patients scored 0 on CHA2DS2-VASc had lower event rates than those scored 0 on CHADS2. Guidelines now prefer CHA2DS2-VASc.
No, they reduce it substantially but not to zero. Patient-level data summaries (such as the NCBI InformedHealth review) illustrate the effect: at a score of 3, about 37 of 1,000 untreated people have a stroke within a year, versus about 13 of 1,000 on anticoagulants. That two-thirds reduction is why the benefit usually outweighs the bleeding risk at higher scores.
Add This Calculator to Your Website
References
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. American College of Cardiology: 10 Points to Remember. Published November 2023. Endorses CHA2DS2-VASc for stroke-risk prediction with flexibility for other validated scores. Accessed October 19, 2026.
- InformedHealth.org. Atrial Fibrillation: Preventing Strokes. NCBI Bookshelf. Score components table and stroke risk with and without anticoagulation. Accessed October 19, 2026.
- Lip GYH, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272. Source of the annual stroke-rate table used in this calculator.
- Olesen JB, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. Danish nationwide validation showing CHA2DS2-VASc identifies truly low-risk patients.
- January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for Management of Patients With Atrial Fibrillation. Circulation. 2019;140:e125-e151. DOAC preference and anticoagulation thresholds by score.
- Medscape. Scores for Stroke Risk Assessment in Atrial Fibrillation. Clinical summary of CHA2DS2-VASc derivation, validation, and limitations including CKD populations. Accessed October 19, 2026.
- Wikidoc. CHA2DS2-VASc Score. Editorial summary of the score's history and validation statistics (c-statistics vs CHADS2). Accessed October 19, 2026.
- American Heart Association. Atrial Fibrillation (AFib). Patient education on AFib, stroke risk, and treatment options at heart.org. Accessed October 19, 2026.
- European Society of Cardiology. 2024 ESC Guidelines for the management of atrial fibrillation. Introduces CHA2DS2-VA (sex criterion removed) for European practice.
- Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093-1100. Bleeding-risk counterpart to stroke-risk scoring.